Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.

All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).

PET-MRI and EBUS-TBNA

Sveinung Sørhaug, MD PhD

The overall aim of this study is to compare standard staging of lung cancer (which includes clinical examination, CT, MRI, bone scan and PET-CT) with comprehensive staging - which includes the new staging methods (PET-MRI and systematic mapping of mediastinal and hilar lymph nodes using endobronchial ultrasound) with respect to disease stage and outcomes of therapy.

The trial is a randomized, explorative study. Patients undergoing examinations for suspicions of lung cancer (Stage I-III) are randomized to either standard diagnostic work-up for lung cancer (Arm A, n=75) or comprehensive diagnostic work-up (Arm B, n=75) with standard examinations plus endobronchial-screening for metastatic lymph nodes (EBUS-TBNA) and PET-MRI.

All patients will undergo todays' standard examination for diagnosing and staging lung cancer. This will be individualized for each patient according to current guidelines. In addition to the standard diagnostic work-up, patients in the interventional group (ArmB) will undergo

1) PET-MRI 2) systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes)

1. PET-MRI PET-MRI will be done immediate after the standard PET-CT using the same infusion of tracer (18-fluorodeoxyglucose, FDG). The sequence protocols used for MRI will be standardized for the study, according to each body compartment. Measurement of Standard Uptake Values (SUV) of the tracer (FDG) will be recorded in pathological lesions. In the mediastinum, each lymph node station will be evaluated with description of visible nodes.
2. Systematic mediastinal mapping The EBUS-TBNA will be done at the initial bronchoscopy and using standard conscious sedation according to the local guidelines at St.Olavs Hospital. Each lymph node station (station 2, 4, 7, 10 and 11 bilateral) will be examined and all lymph nodes ≥ 0,5 cm in short diameter that is easily accessible will be punctured for rapid on-site cytological evaluation (ROSE).

After the initial diagnostic work-up is completed, the patient will be given treatment according to existing guidelines for lung cancer based on the given clinical stage.

For patients undergoing surgery all accessible lymph nodes will be resected according to standard practice. Every resected lymph node will be carefully named according to the standard lymph station for comparison with clinical findings.

Extensive Staging in Lung Cancer

Randomized Study Comparing Standard Staging of Lung Cancer With Extended Staging Including EBUS-TBNA and PET-MRI

Norwegian University of Science and Technology

St. Olavs Hospital

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Breast Neoplasms

Pain

Breast Diseases

Skin Diseases

Anti-Arrhythmia Agents

Channel Blockers

Central Nervous System Depressants

All Drugs and Chemicals

Lidocaine

Anesthetics

Anesthetics, Local

Sodium Channel Blockers

Diuretics, Potassium Sparing

Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)

A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection

A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.

A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.

Lidocaine patch

Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.

Buzzy(R)

Ice cools the skin and can provide some numbing for pain.

Ice pack

Heather B Neuman, MD

The purpose of this study is to compare the effectiveness four different pain treatments for the injection of radioactive tracer that women with breast cancer receive for sentinel lymph node biopsies.

This study will include women who have been diagnosed with breast cancer and who will be undergoing sentinel lymph node biopsy with a standard injection of radioactive tracer before surgery.

A participant's active participation will take place on two separate occasions. In the first occasion, a participant will complete a brief pain assessment on the day of enrollment. The rest of a participant's active participation will take place on one day (the day of surgery) and last approximately 20 minutes, after which active participation will end.

Primary Objective: To test the effectiveness of four alternative approaches to topical anesthesia on pain associated with radiotracer injection for women diagnosed with breast cancer undergoing sentinel lymph node mapping.

Secondary Objectives:

1. To assess patient satisfaction with pain control modality for radiotracer injection.
2. To identify barriers to implementation of the different pain control interventions.

There will be four separate treatment arms. Participants have equal chances of being assigned to any of the four arms.

Data will be analyzed with intervention arms masked.

Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer

Optimizing Topical Pain Control for Breast Cancer Patients Undergoing Pre-operative Radiotracer Injection for Sentinel Lymph Node Mapping

Post-procedural pain score on the Wong-Baker FACES scale. Scale from 0-10 with 0 being "no pain" and 10 being "worst pain".

Sensory pain score out of 33 with 0 being "no pain" and 33 being severe sensory pain

Affective pain score out of 12 with 0 being "no pain" and 12 being severe affective pain

Visual analog scale pain score out of 100 with zero being "no pain" and 100 being "worst possible pain"

Combination of outcomes 2-3. Additive total score between 0 and 45 with zero being "no pain" and 45 being "severe pain"

1-6 scale with 1 being "very satisfied" and 6 being "very dissatisfied". Reported are the number of participants satisfied or very satisfied.

1-4 scale with 1 being "very anxious" and 4 being "not at all anxious", reported here are the number of participants rating anxiety at 2 or "moderate".

"Yes", "No", "Not sure" with option for free response

7 point single ease question to rate ease of a task. 1 being "very difficult" and 7 being "very easy". This is the provider's perception of the how easy the intervention was to administer.

11 point numeric rating scale for perceived pain of others. 0 being "no pain" and 7-10 being "severe pain".

End of study survey to compare providers' perceived usability of intervention. Rank ordering of interventions 1-4 with 1 being "easiest to administer" and 4 being "hardest to administer".

End of study survey to compare providers' perceived efficacy of intervention. Rank ordering of interventions 1-4 with 1 being "best pain control" and 4 being "least pain control".

National Cancer Institute (NCI)

University of Wisconsin, Madison

Ice Pack

A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection.

Lidocaine Patch

Lidocaine Patch and Buzzy(R)

Total

Age, Customized

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Heather B Neuman, MD, MS, FACS

Median Post-Procedural Pain Score

Short Form McGill Sensory Pain Score

Short Form McGill Affective Pain Score

Short Form McGill VAS Pain Score

Short Form McGill Combined Pain Score

Degree of Participant Satisfaction With Attention Paid to Complaints as Reported by Number of Participants Who Report Satisfied or Very Satisfied

Degree of Participant Satisfaction With Care Provided During Injection as Reported by Number of Participants Who Report Satisfied or Very Satisfied

Degree of Participant Satisfaction With Pain Control as Reported by Number of Participants Who Report Satisfied or Very Satisfied

Degree of Anxiety During the Injection as Measured by Number of Participants Moderately Anxious

Recommendation of Pain Control Modality as Measured by Number of Participants Who Answered "Yes"

Provider Perceived Ease of Administration

Provider Perceived Participant Pain

There were 8 providers surveyed to rank the ease of use of the interventions, they were not consented as the IRB considered them 'study team members'

Provider Rank Ordering Ease of Use of Interventions

There were 8 providers that were not consented to the study because the IRB considered the 'study team members'

Provider Rank Ordering Perceived Efficacy of Interventions

Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)

Ice pack: Ice cools the skin and can provide some numbing for pain.

A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.

Buzzy(R): Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.

Ice pack: Ice cools the skin and can provide some numbing for pain.

A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection

Lidocaine patch: Lidocaine is a local anesthetic.

A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.

Lidocaine patch: Lidocaine is a local anesthetic.

Buzzy(R): Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.

Ice pack: Ice cools the skin and can provide some numbing for pain.

Overall Study

Rare Diseases

Neoplasm Metastasis

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Germ Cells Tumors

Nonseminomatous Germ Cell Tumor

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.

Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

K5-RGD PET

Nicolas AIDE, Dr

Arnaud DOERFLER, Dr

Pierre VERA, Dr

The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy.

The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.

Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

Efficacity to differentiate mature teratoma and necroses within the residual masses of germinal non-seminoma tumors.

Number of patients having at least a tumor detected by TEP K5-RGD requiring a surgery, divided by the number of patients having actually at least a tumor (by anatomopathologie) requiring a chirurgie

Centre Francois Baclesse

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

Radiopharmaceuticals

3-Iodobenzylguanidine

The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.

MIBG-I131

Rachel SP Riechelmann, Phd

This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated neuroendocrine tumors and radiological progression or intolerance after standard lines of treatment and with MIBG positive scan.

Neuroendocrine tumors (NET) are rare neoplasms, which frequently present metastatic and incurable at diagnosis. In this context, few effective therapies exist. When the disease becomes refractory to standard therapies, treatments with limited efficacy (eg, surgical debulking, cytotoxic chemotherapies, interferon alpha) that could lead to important adverse events are used. Therefore, clinical studies that test new therapeutic strategies in NET patients with refractory disease are needed. Treatment with radiopharmaceuticals have been studied in NET and showed to be promisor. As an example, is the treatment with Lutetium177 octreotate, disponible in Brazil for decades, and one of the most active therapeutic options to NET.

The radiopharmaceutical MIBG-I131 (metaiodobenzylguanidine linked to Iodine131) is the first treatment choice for patients with paraganglioma/pheochromocytoma (PggF), a rare type of neuroendocrine neoplasm originated from neural ganglia. Patients with this neoplasia are submitted to scintigraphy with MIBG-I131, a norepinephrine analog whose transporter protein is highly expressed in this tumor. If the uptake is positive, patients receive treatment with therapeutic doses of MIBG-I131. The disease control with this intervention could last two years. Old and small studies suggested that MIBG-I131 could also have an activity in other NET besides PggF. Gastrointestinal (GI) or lung NET could have a positive expression on MIBG-I131 scan in up to 50% of the cases. With this rationale, retrospective series reported that MIBG-I131 could offer clinical benefit in patients with GI NET, with disease control in up to 80% of the cases. However, the literature regarding therapeutic MIBG-I131 to NET not PggF is scarce, heterogeneous regarding population, methods of response assessment, doses of the radiopharmaceutical, and short follow-up time. Therefore, due to the absence of effective therapeutic options for patients with metastatic well-differentiated NET refractory to standard treatments, the evidence that NET can have a positive expression on MIBG-I131 scan, and that small retrospective studies with a low level of evidence suggest a benefit for control disease and improvement of symptoms, the investigators proposed a phase II study of MIBG-I131 to well-differentiated GI or lung NET patients with positive MIBG-I131 scan.

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors

Phase II Study of MIBG-I131 (Metaiodobenzylguanidine) in Patients With Well Differentiated Neuroendocrine Tumors and MIBG Positive Scan

Defined by absence of radiological progression in conventional imaging examinations by RECIST 1.1.

Quality of life questionnaire (QLQ), assessed by the European Organisation for Research and Treatment of Cancer Quality of Life for Neuroendocrine Tumors (EORTC QLQ-GINET21) (score ranging from 0 to 100, with higher scores meaning better state of the patient). Improvement in at least 10% of the baseline score will be considered positive.

Defined by time from day 1 cycle 1 to death from any cause or radiological progression by RECIST 1.1, whichever occurs first. Patients alive and without progression at the time of study analysis will be censored for time-to-event analysis.

Defined by at least 30 percent drop in the tumor marker (24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) and/or specific hormone), if functioning syndrome, at any time of treatment in relation to pre-treatment value.

Frequency of adverse events of grades 2 or more by CTCAE version 5.0.

AC Camargo Cancer Center

Head of Medical Oncology Department

Neuroblastoma

Neuroectodermal Tumors, Primitive, Peripheral

Neoplasms, Neuroepithelial

Neoplasms, Glandular and Epithelial

Enzyme Inhibitors

Iobenguane I 123 Injection

Arnold Jacobson, MD

GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection (\[123I\]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for \[123I\]mIBG imaging.

The sponsor will provide \[123I\]mIBG as a single dose in a ready-to-use vial. All patients greater than or equal to 18 years of age and children with a weight of greater than or equal to 70 kg will receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq \[9.0 to 11 mCi\]) of \[123I\]mIBG. Children \<16 years of age (with a weight of 8-70 kg) will receive an activity of \[123I\]mIBG calculated on the basis of a reference activity for an adult scaled to body weight. Each investigator is responsible for obtaining the appropriate thyroid blockade agent and for its administration in accordance with national and local regulations and guidelines. Approximately 24 (± 6) hours following administration of \[123I\]mIBG all patients will return to the clinic for scintigraphic imaging. Imaging will be performed as per the standard procedures of the investigational site. This should include at a minimum total body planar scintigraphy. Single photon emission computed tomography (SPECT) may be performed following planar scintigraphy, as appropriate.

Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

GE Healthcare

Arnold F. jacobson, M.D., PhD./Clinical Project Leader

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Urogenital Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Prostatic Diseases

Male Urogenital Diseases

Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.

Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.

FACBC PET-CT

Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.

MRI, CT, or Bone Scan

David Schuster, MD

The purpose of this study is to assess if using anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment. Investigators will enroll participants whose cancer has been treated with hormone therapy and now the cancer is not responding to the treatment (castration -resistant), and so therefore will be started on chemotherapy. Investigators aim to enroll thirty participants in this study.

The goal of the investigation is to examine therapeutic monitoring of chemotherapy in castrate resistant prostate carcinoma with anti-3-\[18F\]FACBC in prostate carcinoma to determine if anti-3-\[18F\]FACBC amino acid imaging can serve as an accurate and efficient imaging biomarker.

Investigators will perform a baseline anti-3-\[18F\]FACBC PET-CT of the whole body. All participants will also undergo conventional staging including 99mTc methylene diphosphonate (MDP) bone scanning and computed tomography scan (CT) or magnetic resonance imaging (MR) of the abdomen and pelvis which are standard of care at the enrolling institution. This study will not interfere with standard patient evaluation or delay therapy.

All 30 participants will receive chemotherapy every 3 weeks for 6 cycles. Participants will undergo a repeat anti-3-\[18F\]FACBC PET-CT after 1 and 6 cycles and also repeat conventional imaging including bone scanning CT or MR of the abdomen and pelvis after 6 cycles. At the end of the study, the study team will then record the response (or lack thereof) on anti-3-\[18F\]FACBC PET-CT and correlate that response with response per standard clinical criteria including bone scan uptake for skeletal lesions, CT or MR for soft tissue and skeletal lesions, prostate-specific antigen (PSA) progression or regression, and other clinical parameters such as declining performance status.

FACBC Prostate Therapy Response

Investigation of Therapy Response With Amino Acid Analogue Transport PET Imaging

Clinical response will be assessed with FACBC PET imaging. The same measurements of the lesions and background structures will be undertaken at baseline and post-therapy scan. The researchers utilized the following parameters to follow response to therapy: maximum standardized uptake value (SUVmax) of most intense lesion each of bone and node, sum and mean SUVmax of up to 5 index lesions for each of bone and node of most intense lesion each of bone and node of the 5 index lesions for each of bone and node. SUVmax measures uptake of the radiotracer by malignant cells. Percent change after therapy, compared to baseline, was calculated and a positive percent increase indicates greater uptake of FACBC by cancer cells.

Prostate Specific Antigen (PSA) serum biomarker will be used to assess response to treatment. PSA level will be collected via blood draw. While a formal cutpoint signifying prostate cancer is not generally used as PSA levels vary between men, in general, higher PSA levels indicate prostate cancer.

Participants will have an MRI or a CT scan to assess response to treatment. Treatment response will be reported as follows:

* Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
* Complete Response Unknown (CRU)
* Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
* Stable Disease (NR/SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
* Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm.

A CT will be used to assess response to treatment. Treatment response will be reported as follows:

* Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
* Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
* Stable Disease (NR/SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
* Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm.

Each patient underwent 99mTc MDP whole body bone scanning at baseline, and after the 6th cycle. Bone scans findings were interpreted based on recommendations from Prostate Cancer Clinical Trial Working Group 3 (PCCTWG3) using a specialized Bone Scan Assessment Tool. The change in disease response after cycle 6 compared to the baseline assessment is presented here.

The number of deaths that have occurred was assessed at the end of study.

Blue Earth Diagnostics

Nihon Medi-Physics Co., Ltd.

Emory University

Associate Professor

Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement receiving Anti-3-\[18F\]FACBC radiotracer intravenously prior to PET scan.

Age, Categorical

Age, Continuous

Percent change between Baseline and Cycle 1

Percent change between Baseline and Cycle 6

This analysis includes participants completing the study visits used in each change from baseline determination.

Percent Change Assessed by FACBC PET Scan

Baseline

After completing Cycle 1

After completing Cycle 6

This analysis includes participants completing the study visits.

Prostate Specific Antigen Level

Data were not collected for this outcome measure as all participants had a CT scan rather than an MRI to assess response to treatment.

Number of Participants Responding to Treatment Assessed by MRI

This analysis includes participants completing the study.

Number of Participants Responding to Treatment Assessed by CT Scan

This analysis includes participants who completed the study.

Number of Participants With a Clinical Response Assessed by Bone Scan

Number of Deaths

Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement receiving anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC) radiotracer intravenously prior to positron emission tomography (PET) scan.

Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.

Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Extensive Staging in Lung Cancer	NCT02030444	Lung Neoplasms	PET-MRI and EBU...	-	St. Olavs Hospital
Extensive Staging in Lung Cancer	NCT02030444	Lung Neoplasms	PET-MRI and EBU...	-	St. Olavs Hospital
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer	NCT04822597	Breast Cancer Sentinel Lymph ... Breast Neoplasm... Breast Cancer F...	Lidocaine patch Buzzy(R) Ice pack	18 Years -	University of Wisconsin, Madison
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy	NCT02317393	Non-seminomatou... Metastasis	K5-RGD PET FDG	18 Years -	Centre Francois Baclesse
Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors	NCT04831567	Neuroendocrine ...	MIBG-I131	18 Years -	AC Camargo Cancer Center
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma	NCT00730444	Neuroblastoma	Iobenguane I 12...	-	GE Healthcare
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma	NCT00730444	Neuroblastoma	Iobenguane I 12...	-	GE Healthcare
FACBC Prostate Therapy Response	NCT02830880	Prostate Cancer	FACBC PET-CT MRI, CT, or Bon...	18 Years -	Emory University
Hand-held Gamma Camera in the SNOLL Procedure	NCT02101320	Breast Cancer	TRECAM	19 Years -	Assistance Publique - Hôpitaux de Paris
Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.	NCT06136377	Patients With M...	177Lu-PSMA-617 ...	18 Years -	Centre Georges Francois Leclerc
FACBC Prostate Therapy Response	NCT02830880	Prostate Cancer	FACBC PET-CT MRI, CT, or Bon...	18 Years -	Emory University

Spots Global Cancer Trial Database for nuclear medicine